Imprimis

Imprimis Pharmaceuticals (NASDAQ: IMMY) is a growing player in the ophthalmology eye drop market. Benzinga recently spoke with Imprimis CEO Mark Baum about what investors should expect going forward. Benzinga: You had earnings last Thursday, and you mentioned that you see revenue growth...